{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:16:02Z","timestamp":1792440962451,"version":"4.5.0"},"reference-count":50,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec id=\"S0317167121001530_as1\"><jats:title>Background:<\/jats:title><jats:p>The PREDICT study assessed real-world, long-term health-related quality of life in adults with chronic migraine (CM) receiving onabotulinumtoxinA.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167121001530_as2\"><jats:title>Methods:<\/jats:title><jats:p>Canadian, multicenter, prospective, observational study in adults na\u00efve to onabotulinumtoxinA for CM. OnabotulinumtoxinA (155\u2013195 U) was administered every 12 weeks over 2 years (\u22647 treatment cycles). Primary endpoint: mean change in Migraine-Specific Quality of Life Questionnaire (MSQ) at treatment 4 (Tx4) versus baseline. Secondary endpoints: mean change in MSQ at final visit versus baseline, and headache days.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167121001530_as3\"><jats:title>Results:<\/jats:title><jats:p>184 participants (average age 45 years; 84.8% female; 94.6% Caucasian) received \u22651 onabotulinumtoxinA treatment; 150 participants completed 4 treatments (1 year) and 123 completed all 7 treatment cycles (2 years). Mean (SD) onabotulinumtoxinA dose per treatment cycle was 171 (18) U and treatment interval was 13.2 (1.8) weeks. Baseline mean (SD) 20.9 (6.7) headache days\/month decreased (Tx1: \u22123.5 [6.3]; Tx4: \u22126.5 [6.6]; <jats:italic>p<\/jats:italic> &lt; 0.0001 versus baseline). Mean (SD) increased from baseline in MSQ at Tx4 (restrictive: 21.5 [24.3], preventive: 19.5 [24.7], emotional: 22.9 [32.9]) and the final visit (restrictive: 21.3 [23.0], preventive: 19.2 [23.7], emotional: 27.4 [30.7]), exceeding minimal important differences (all <jats:italic>p<\/jats:italic> &lt; 0.0001). Seventy-seven (41.8%) participants reported 168 treatment-emergent adverse events (TEAEs); 38 TEAEs (12.0%) were considered treatment-related. Four (2.2%) participants reported six serious TEAEs; none were considered treatment-related. No new safety signals were identified.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167121001530_as4\"><jats:title>Conclusions:<\/jats:title><jats:p>Real-world evidence from PREDICT demonstrates that onabotulinumtoxinA for CM in Canada improved MSQ scores and reduced headache frequency and severity, adding to the body of evidence on the long-term safety and effectiveness of onabotulinumtoxinA for CM.<\/jats:p><\/jats:sec>","DOI":"10.1017\/cjn.2021.153","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T08:44:40Z","timestamp":1625474680000},"page":"540-552","source":"Crossref","is-referenced-by-count":13,"title":["OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study"],"prefix":"10.1017","volume":"49","author":[{"given":"Guy","family":"Boudreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie","family":"Graboski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meetu","family":"Bhogal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Davidovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner J.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"S0317167121001530_ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-016-1539-0"},{"key":"S0317167121001530_ref10","doi-asserted-by":"publisher","DOI":"10.1111\/head.12774"},{"key":"S0317167121001530_ref34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804295.x"},{"key":"S0317167121001530_ref24","doi-asserted-by":"publisher","DOI":"10.1111\/head.13849"},{"key":"S0317167121001530_ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01941.x"},{"key":"S0317167121001530_ref27","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364677"},{"key":"S0317167121001530_ref8","doi-asserted-by":"publisher","DOI":"10.1111\/head.12755"},{"key":"S0317167121001530_ref33","unstructured":"33. Botox [product monograph]. Markham, ON, Canada: Allergan; 2014."},{"key":"S0317167121001530_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/head.13089"},{"key":"S0317167121001530_ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0976-1"},{"key":"S0317167121001530_ref43","volume-title":"Manual for the Beck Depression Inventory-II","author":"Beck","year":"1996"},{"key":"S0317167121001530_ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616677005"},{"key":"S0317167121001530_ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0676-z"},{"key":"S0317167121001530_ref11","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000323925.29520.e7"},{"key":"S0317167121001530_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013"},{"key":"S0317167121001530_ref1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"S0317167121001530_ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3393-3"},{"key":"S0317167121001530_ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00950.x"},{"key":"S0317167121001530_ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0784-4"},{"key":"S0317167121001530_ref32","doi-asserted-by":"publisher","DOI":"10.1111\/head.13074"},{"key":"S0317167121001530_ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01766.x"},{"key":"S0317167121001530_ref39","unstructured":"39. National Institute for Health and Care Excellence (NICE). Botulinum toxin type A for the prevention of headaches in adults with chronic migraine; 2012. Available at: https:\/\/www.nice.org.uk\/guidance\/ta260\/chapter\/1-Guidance. Accessed on July 26, 2021."},{"key":"S0317167121001530_ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-007-9217-1"},{"key":"S0317167121001530_ref44","doi-asserted-by":"publisher","DOI":"10.1111\/head.12878"},{"key":"S0317167121001530_ref35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00030.x"},{"key":"S0317167121001530_ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01990.x"},{"key":"S0317167121001530_ref46","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13657"},{"key":"S0317167121001530_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"S0317167121001530_ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02265.x"},{"key":"S0317167121001530_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.11.004"},{"key":"S0317167121001530_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8"},{"key":"S0317167121001530_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/head.13661"},{"key":"S0317167121001530_ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1030-z"},{"key":"S0317167121001530_ref50","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"S0317167121001530_ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01555.x"},{"key":"S0317167121001530_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"S0317167121001530_ref25","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364676"},{"key":"S0317167121001530_ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.124"},{"key":"S0317167121001530_ref17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.7.1011"},{"key":"S0317167121001530_ref14","first-page":"1052","article-title":"Preventive therapy of migraine","volume":"24","author":"Schwedt","year":"2018","journal-title":"Continuum (Minneap Minn)."},{"key":"S0317167121001530_ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0840-8"},{"key":"S0317167121001530_ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00990.x"},{"key":"S0317167121001530_ref9","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.1.3.391"},{"key":"S0317167121001530_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.01.010"},{"key":"S0317167121001530_ref21","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1671350"},{"key":"S0317167121001530_ref19","first-page":"670","article-title":"Guideline for primary care management of headache in adults","volume":"61","author":"Becker","year":"2015","journal-title":"Can Fam Physician."},{"key":"S0317167121001530_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15440-8"},{"key":"S0317167121001530_ref47","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-54"},{"key":"S0317167121001530_ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01365.x"},{"key":"S0317167121001530_ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01678.x"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167121001530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T01:10:16Z","timestamp":1656551416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167121001530\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0317167121001530"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2021.153","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]}}}